Vibegron shows efficacy among patients with OAB

January 7, 2022

“This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well,” says Cornelia Haag-Molkenteller, MD. PhD.

In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the background and findings of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.